Properties (61)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
company
|
| gptkbp:acquisition |
gptkb:Viveve_Medical,_Inc.
|
| gptkbp:CEO |
gptkb:Dr._J._Michael_Bishop
|
| gptkbp:clinicalTrials |
Phase 1, Phase 2, Phase 3
multiple ongoing various stages of development aims to improve clinical outcomes collects clinical data for analysis conducts clinical research trials conducts patient trials develops therapeutic candidates. focused on therapeutic development involved in biopharmaceuticals development |
| gptkbp:collaborations |
academic institutions
engaged in collaborative projects |
| gptkbp:communityEngagement |
active in patient advocacy
|
| gptkbp:communityPartnerships |
forms healthcare partnerships
|
| gptkbp:employees |
over 100
|
| gptkbp:financialPerformance |
strong financial growth
volatile stock performance |
| gptkbp:focus |
cancer therapeutics
|
| gptkbp:founded |
2006
|
| gptkbp:founder |
gptkb:Dr._J._Michael_Bishop
|
| gptkbp:globalPresence |
operates internationally
|
| gptkbp:hasPrograms |
has a scientific advisory board
|
| gptkbp:hasResearchInterest |
conducts market research studies
|
| gptkbp:headCoach |
gptkb:Dr._J._Michael_Bishop
|
| gptkbp:headquarters |
gptkb:Newark,_Delaware
|
| gptkbp:healthcare |
dedicated to patient care initiatives
|
| gptkbp:historicalResearch |
with leading research institutions
|
| https://www.w3.org/2000/01/rdf-schema#label |
SRNE
|
| gptkbp:industry |
biotechnology
|
| gptkbp:innovation |
driven by innovation in therapies
|
| gptkbp:investmentFocus |
institutional and retail investors
significant venture capital funding maintains investor relations program |
| gptkbp:leadership |
experienced management team
|
| gptkbp:market |
approximately $1 billion
|
| gptkbp:marketSegment |
focused on niche markets
|
| gptkbp:mission |
develop innovative therapies
|
| gptkbp:partnerships |
various pharmaceutical companies
strategic partnerships with biotech firms |
| gptkbp:patentCitation |
numerous granted patents
|
| gptkbp:products |
gptkb:Sorrento_Therapeutics
ongoing product development efforts |
| gptkbp:regulatoryCompliance |
FDA_approvals_for_certain_products
|
| gptkbp:research |
secured funding for research projects
|
| gptkbp:research_areas |
oncology
|
| gptkbp:researchAreas |
immunotherapy
|
| gptkbp:researchInterest |
numerous peer-reviewed articles
receives research grants |
| gptkbp:revenue |
growing revenue stream
|
| gptkbp:socialResponsibility |
commitment to ethical practices
|
| gptkbp:stockSymbol |
gptkb:SRNE
|
| gptkbp:subsidiary |
gptkb:Sorrento_Therapeutics,_Inc.
|
| gptkbp:technology |
proprietary technology platform
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
various drug candidates
|
| gptkbp:usesTechnology |
operates in the biotech sector
|
| gptkbp:vision |
transforming cancer treatment
|
| gptkbp:website |
www.sorrentotherapeutics.com
|